ALBUQUERQUE, NM — (Marketwire) — 10/05/11 — Lovelace Respiratory Research Institute (LRRI) announced it has received an IDIQ (Indefinite Delivery Indefinite Quantity) contract from the U.S. Navy Medicine with a potential value of up to $497M. This contract covers key medical problems that Marines, soldiers, sailors and airmen face in war zones, such as biomedical and psychological issues, and clinical research. The award represents a three year base contract with an additional option of two years. LRRI is one of 27 Companies that will be allowed to bid on individual task orders to deliver research and development services.
Joining the LRRI team is PPD, Ernst & Young, and the Geneva Foundation, providing the Navy extensive expertise in curing and treating diseases that American military men and women face in the field.
“LRRI has nearly 65 years proven experience in respiratory research, including collaboration with the Defense Community to research chemical, biological and radiological threats, ” said Robert W. Rubin, President and CEO of LRRI. “Our scientists provide expert research protocol and data to many industries, and we are pleased to be selected as one of the contractors to help the U.S. Navy prepare for our nation–s readiness and defense capabilities.”
The Lovelace Respiratory Research Institute (LRRI) is a private, biomedical research organization dedicated to improving public health through research on the prevention, treatment and cure of respiratory disease. LRRI is committed to curing respiratory diseases through research aimed at understanding their causes and biological mechanisms; assessing and eliminating exposures to respiratory health hazards; and developing improved therapeutics, vaccines, and diagnostics. LRRI is based in Albuquerque, New Mexico, employs 1100 people, and is a $125 million company.
Contact:
Kyla Thompson
505-341-0699